IC19 chimeric antigen receptor T cell therapy (Beijing Immunochina Medical Science & Technology Co Ltd)

N/A

Report date: 2025/07/26 20:00:09

Base Information

Drug NameIC19 chimeric antigen receptor T cell therapy (Beijing Immunochina Medical Science & Technology Co Ltd)

Drug Alias NameIC19 CAR-T Cell TherapyIC19

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacementsImmunologic cytotoxicity

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLupus Erythematosus, Systemic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesImunopharm Technology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesImunopharm Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsLupus Erythematosus, Systemic

Inactive IndicationsN/A

Other Information

ATC CodeN/A